Inmune Bio, INC Form 4 insider transactions

Director Timothy Schroeder acquired 12,500 options in Inmune Bio, Inc. under the company's 2021 Stock Incentive Plan.

David Moss, CFO of Inmune Bio, Inc., reports the acquisition of 160,000 stock options on May 14, 2024.

Mark William Lowdell, Chief Scientific Officer of Inmune Bio Inc., reports the acquisition of 100,000 stock options.

Director Scott Juda acquired options to purchase 12,500 shares of Inmune Bio stock at $9.92 per share, vesting monthly over one year.

Director James Kelly Ganjei acquired options to purchase 12,500 shares of Inmune Bio, Inc. common stock on May 14, 2024.

Director Edgardo Baracchini Jr. acquired options to purchase 12,500 shares of Inmune Bio, Inc. common stock, according to a recent SEC filing.

Director Marcia Allen reports receiving a stock option grant from Inmune Bio, Inc.

Inmune Bio's CFO, David Moss, purchased shares and warrants in a registered direct offering, amending a previous filing to correct a reporting error.

Inmune Bio's CEO, Raymond Joseph Tesi, purchased shares and warrants in a registered direct offering, increasing his holdings in the company.

Mark William Lowdell, Chief Scientific Officer of Inmune Bio, Inc., purchased shares and warrants in a registered direct offering, increasing his holdings in the company.

Director Scott Juda purchased 29,603 shares of Inmune Bio common stock and warrants in a registered direct offering.

Inmune Bio's CEO, Raymond Joseph Tesi, acquired 18,028 shares of common stock and warrants in a registered direct offering, increasing his beneficial ownership in the company.

David Moss, CFO, Treasurer, and Secretary of Inmune Bio, Inc., reports the acquisition of common stock and warrants through a registered direct offering.

Mark William Lowdell, Chief Scientific Officer of Inmune Bio, Inc., acquired additional shares and warrants through a registered direct offering, increasing his beneficial ownership in the company.

Director Scott Juda purchased 29,603 shares of Inmune Bio stock and warrants in a registered direct offering.